PDCD1 and non-small cell lung carcinoma: In particular, in patients with NSCLC, anti-PD-1/PD-L1 therapy has shown the greatest significant benefit in OS, long-term responses, and a good safety profile, including naïve and pretreated patients, regardless of the histological subtype.